BioSpace News Archive

New global survey shows increased confidence in science; 3M calls for renewed focus on sustainability; STEM equity and collaboration to help solve the world’s greatest challenges

GemVax & KAEL a clinical stage company developing novel immunotherapies based on telomerase modification announced the decision to apply for an expanded access IND for its lead candidate GV1001 to include additional investigational groups in Alzheimer’s, a disease the WHO estimates to affect 24 million people worldwide, in its clinical development program.

Lamon to oversee business development strategy and execution, and brings over 15 years of pharmaceutical and academia experience to the company

The next generation decision-support platform restores an evidence-based approach to molecular diagnostics and oncology

Avivagen Inc., a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce multiple introductory purchase orders for OxC-betaTM Livestock with new clients in Mexico.

Consumable product portfolio a natural extension for STERIS’s Customers in sterile processing departments, operating rooms and endoscopy

Brickell Biotech, Inc. announced the initiation of its first pivotal U.S. Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis.

The Medicom Group, one of the world’s leading manufacturers of surgical and respiratory masks, announced the expansion of its U.S. mask manufacturing operations.

EIP Pharma, Inc., a CNS-focused therapeutics company, announced that the Phase 2 AscenD-LB study in patients with mild-to-moderate dementia with Lewy bodies met its primary endpoint of demonstrating an improvement in cognition as assessed by the Neuropsychological Test Battery.

Verastem, Inc., a biopharmaceutical company committed to advancing new medicines for patients battling cancer, announced the grant of options to purchase 39,000 shares of its common stock to three new employees and the grant of 22,500 restricted stock units to two of the three new employees.